These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 28504191

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.
    Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302
    [Abstract] [Full Text] [Related]

  • 48. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
    Oscherwitz J, Yu F, Jacobs JL, Cease KB.
    Clin Vaccine Immunol; 2013 Mar 01; 20(3):341-9. PubMed ID: 23283638
    [Abstract] [Full Text] [Related]

  • 49. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
    Wui SR, Kim HK, Han JE, Kim JM, Kim YH, Chun JH, Cho YJ, Lee NG.
    Int Immunopharmacol; 2011 Sep 01; 11(9):1195-204. PubMed ID: 21492746
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine.
    McComb RC, Martchenko M.
    Vaccine; 2016 Jan 02; 34(1):13-9. PubMed ID: 26611201
    [Abstract] [Full Text] [Related]

  • 56. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M, Roehrl MH, Basar E, Wang JY.
    Vaccine; 2008 Feb 13; 26(7):947-55. PubMed ID: 18192092
    [Abstract] [Full Text] [Related]

  • 57. Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.
    Oscherwitz J, Quinn CP, Cease KB.
    Vaccine; 2015 May 11; 33(20):2342-6. PubMed ID: 25820066
    [Abstract] [Full Text] [Related]

  • 58. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
    Reed MD, Wilder JA, Mega WM, Hutt JA, Kuehl PJ, Valderas MW, Chew LL, Liang BC, Squires CH.
    PLoS One; 2015 May 11; 10(7):e0130952. PubMed ID: 26207820
    [Abstract] [Full Text] [Related]

  • 59. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
    Gubbins MJ, Schmidt L, Tsang RS, Berry JD, Kabani A, Stewart DI.
    J Immunoassay Immunochem; 2007 May 11; 28(3):213-25. PubMed ID: 17613668
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.